The effect of ethinyloestradiol on calcium and phosphorus metabolism of post menopausal women with primary hyperparathyroidism

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Eight post menopausal women with primary hyperparathyroidism were given ethinyloestradiol (0.05 mg daily) and the effects on calcium and phosphorus metabolism were observed. In every patient ethinyloestradiol produced a fall in fasting plasma and urine calcium. Calcium balance improved in 7 patients on treatment and there was a significant fall in 24 hr urine calcium in all 8 patients; however, there was no consistent change in net or true absorption of calcium. Ethinyloestradiol produced a small fall in the fasting plasma inorganic phosphorus and a fall in fasting urine phosphorus in 7 cases. There was a decrease in 24 hr urine phosphorus in 7 of the 8 cases, but there was no consistent effect on phosphorus absorption nor on phosphorus balance. Bone mineralization rate and bone resorption rate were determined in 7 of the patients. The administration of ethinyloestradiol produced a decrease in both these variables in all 7 patients. The 24 hr urine hydroxyproline, used as an independent measure of bone resorption, decreased in all 8 patients during ethinyloestradiol therapy. It is concluded that ethinyloestradiol produces an improvement in calcium and phosphorus balance and a decrease in plasma calcium and phosphorus in primary hyperparathyroidism by decreasing bone resorption. It is suggested that ethinyloestradiol may be used as a medical treatment for primary hyperparathyroidism in post menopausal women who are either unsuitable for surgery or on whom operative procedures have failed, or in those cases in whom primary hyperparathyroidism is mild.

Original languageEnglish
Pages (from-to)785-802
Number of pages18
JournalClinical Science and Molecular Medicine
Volume45
Issue number6
StatePublished - 1973
Externally publishedYes

Fingerprint

Ethinyl Estradiol
Primary Hyperparathyroidism
Phosphorus
Calcium
Urine
Bone Resorption
Fasting
Physiologic Calcification
Hydroxyproline
Operative Surgical Procedures
Therapeutics
Bone and Bones

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

@article{81c61619485e4de0b57cfcd5732fc240,
title = "The effect of ethinyloestradiol on calcium and phosphorus metabolism of post menopausal women with primary hyperparathyroidism",
abstract = "Eight post menopausal women with primary hyperparathyroidism were given ethinyloestradiol (0.05 mg daily) and the effects on calcium and phosphorus metabolism were observed. In every patient ethinyloestradiol produced a fall in fasting plasma and urine calcium. Calcium balance improved in 7 patients on treatment and there was a significant fall in 24 hr urine calcium in all 8 patients; however, there was no consistent change in net or true absorption of calcium. Ethinyloestradiol produced a small fall in the fasting plasma inorganic phosphorus and a fall in fasting urine phosphorus in 7 cases. There was a decrease in 24 hr urine phosphorus in 7 of the 8 cases, but there was no consistent effect on phosphorus absorption nor on phosphorus balance. Bone mineralization rate and bone resorption rate were determined in 7 of the patients. The administration of ethinyloestradiol produced a decrease in both these variables in all 7 patients. The 24 hr urine hydroxyproline, used as an independent measure of bone resorption, decreased in all 8 patients during ethinyloestradiol therapy. It is concluded that ethinyloestradiol produces an improvement in calcium and phosphorus balance and a decrease in plasma calcium and phosphorus in primary hyperparathyroidism by decreasing bone resorption. It is suggested that ethinyloestradiol may be used as a medical treatment for primary hyperparathyroidism in post menopausal women who are either unsuitable for surgery or on whom operative procedures have failed, or in those cases in whom primary hyperparathyroidism is mild.",
author = "Gallagher, {John Christopher G.} and R. Wilkinson",
year = "1973",
language = "English",
volume = "45",
pages = "785--802",
journal = "Clinical Science",
issn = "0143-5221",
publisher = "Portland Press Ltd.",
number = "6",

}

TY - JOUR

T1 - The effect of ethinyloestradiol on calcium and phosphorus metabolism of post menopausal women with primary hyperparathyroidism

AU - Gallagher, John Christopher G.

AU - Wilkinson, R.

PY - 1973

Y1 - 1973

N2 - Eight post menopausal women with primary hyperparathyroidism were given ethinyloestradiol (0.05 mg daily) and the effects on calcium and phosphorus metabolism were observed. In every patient ethinyloestradiol produced a fall in fasting plasma and urine calcium. Calcium balance improved in 7 patients on treatment and there was a significant fall in 24 hr urine calcium in all 8 patients; however, there was no consistent change in net or true absorption of calcium. Ethinyloestradiol produced a small fall in the fasting plasma inorganic phosphorus and a fall in fasting urine phosphorus in 7 cases. There was a decrease in 24 hr urine phosphorus in 7 of the 8 cases, but there was no consistent effect on phosphorus absorption nor on phosphorus balance. Bone mineralization rate and bone resorption rate were determined in 7 of the patients. The administration of ethinyloestradiol produced a decrease in both these variables in all 7 patients. The 24 hr urine hydroxyproline, used as an independent measure of bone resorption, decreased in all 8 patients during ethinyloestradiol therapy. It is concluded that ethinyloestradiol produces an improvement in calcium and phosphorus balance and a decrease in plasma calcium and phosphorus in primary hyperparathyroidism by decreasing bone resorption. It is suggested that ethinyloestradiol may be used as a medical treatment for primary hyperparathyroidism in post menopausal women who are either unsuitable for surgery or on whom operative procedures have failed, or in those cases in whom primary hyperparathyroidism is mild.

AB - Eight post menopausal women with primary hyperparathyroidism were given ethinyloestradiol (0.05 mg daily) and the effects on calcium and phosphorus metabolism were observed. In every patient ethinyloestradiol produced a fall in fasting plasma and urine calcium. Calcium balance improved in 7 patients on treatment and there was a significant fall in 24 hr urine calcium in all 8 patients; however, there was no consistent change in net or true absorption of calcium. Ethinyloestradiol produced a small fall in the fasting plasma inorganic phosphorus and a fall in fasting urine phosphorus in 7 cases. There was a decrease in 24 hr urine phosphorus in 7 of the 8 cases, but there was no consistent effect on phosphorus absorption nor on phosphorus balance. Bone mineralization rate and bone resorption rate were determined in 7 of the patients. The administration of ethinyloestradiol produced a decrease in both these variables in all 7 patients. The 24 hr urine hydroxyproline, used as an independent measure of bone resorption, decreased in all 8 patients during ethinyloestradiol therapy. It is concluded that ethinyloestradiol produces an improvement in calcium and phosphorus balance and a decrease in plasma calcium and phosphorus in primary hyperparathyroidism by decreasing bone resorption. It is suggested that ethinyloestradiol may be used as a medical treatment for primary hyperparathyroidism in post menopausal women who are either unsuitable for surgery or on whom operative procedures have failed, or in those cases in whom primary hyperparathyroidism is mild.

UR - http://www.scopus.com/inward/record.url?scp=0015835705&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0015835705&partnerID=8YFLogxK

M3 - Article

VL - 45

SP - 785

EP - 802

JO - Clinical Science

JF - Clinical Science

SN - 0143-5221

IS - 6

ER -